Huber Engineered Materials, a business unit of J.M. Huber Corp, has named Michael Carpenter as business segment leader, pharmaceutical excipients and food ingredients & nutritional businesses. Carpenter was most recently with Callery Chemical Company, where he was director of pharmaceutical sales and marketing.
Dr Karl Fry has been appointed as manager of quality services by Brecon Pharmaceuticals, which provides commercial and clinical trials packaging services to the healthcare sector. He joins from Penn Pharma- ceutical Services, where he held posts as head of quality assurance and manager of the research & development laboratory. He is also a Qualified Person under the permanent provisions.
Foster Wheeler has appointed Gary T. McMinn as regional vice president, business development, for pharmaceuticals, biotechnology and healthcare. Based in the US, McMinn will develop local and global opportunities for Foster Wheeler with US clients.
Ingenium Pharmaceuticals, of Munich in Germany, has appointed Dr Klaus Dembowsky as vice president drug discovery. He will lead r&d activities, focusing on advancing IngeniumÕs internal drug discovery portfolio toward clinical testing. Dr Dembowsky joins Ingenium from Bayer Corporation, where he spent more than 10 years in drug discovery and development, most recently as a manager of the Bayer-Millennium collaboration for drug target discovery.
Dan Calvo has joined US-based Cellomics as president and ceo. He was formerly vice president of worldwide sales and service at PerkinElmer Life Sciences. He succeeds Dr D. Lansing Taylor, who will remain as chairman of the board of directors.
Instem-LSS, a leading provider of information solutions to the world's pharmaceutical, chemical and contract research organisations, has appointed Jim McLauchlan as its chief financial officer. Based at Instem's UK offices, he will oversee all accounting and strategic financial planning activities for the organisation, which also has offices in the US.
Dr Norbert Dieterich has been named as the new head of Clariant Pharmaceuticals, the pharmaceuticals business unit of Clariant's life sciences and electronic chemicals division. In his new role he will lead a business that draws together the global cGMP manufacturing capability of Clariant along with pharmaceutical services, r&d and technology development assets to work as a world-scale outsourcing partner.